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Background: B-type natriuretic peptide has been used as a biological marker for prognosis in
patients with acute coronary syndrome (ACS). However, a relation between the quantity of
BNP levels and the severity of coronary artery disease has not been systematically
evaluated.
Methods: 197 patients with ACS without ST elevation with normal LV systolic function were
enrolled. BNP was measured in all recruited patients within 12 h of hospitalization. All
patients underwent coronary angiography. We correlated BNP levels in patients with
unstable angina (USAP) and non ST-elevation myocardial infarction (NSTEMI) with
angiographic disease severity including Gensini Score.
Results: BNP levels were significantly higher in the NSTEMI group in comparison to the
USAP Group (161  149.3 vs 79.6  94.2 pg/mL; p < 0.001). BNP levels rose significantly with
increasing number of vessels involved (1-vessel ¼ 51.4  31.6; 2-vessels ¼ 114.0  67.8; 3
vessels ¼ 265.4  188.8 pg/mL, p < 0.001). Most importantly, BNP> 80 pg/ml was found to
strongly predict the presence of Triple vessel disease (odds ratio 18.87; 95% confidence
intervals 5.36e66.36), and Double vessel disease (odds ratio 3.62; 95% confidence intervals
1.75e7.47). In single vessel group, BNP was significantly higher when LAD was involved
vessel (64.78 vs 49.76 pg/mL, p < 0.05).
Gensini Score showed a strong correlation with BNP levels (r ¼ 0.675, p < 0.01), and
Gensini Score was significantly higher in those with BNP> 80 pg/ml (40.9  29.7 vs
13.4  16.5 p < 0.001).
Conclusion: Circulating BNP levels appear elevated in Non ST Elevation ACS, even in the
absence of LV systolic dysfunction. High BNP levels are associated with multi-vessel
disease and diffuse coronary atherosclerosis.
Copyright ª 2013, Cardiological Society of India. All rights reserved..
l.com (B.M. Goyal).
2013, Cardiological Society of India. All rights reserved.
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) 1 8 3e1 8 71841. Introduction
B-type natriuretic peptide (BNP) is a peptide consisting of 32
aminoacids produced by the myocytes as a prohormone. It is
released in response to ventricular dilatation and pressure
overload, in its active form after peptidase degradation, into
the cardiovascular system.1
BNP levels are increased after myocardial infarction and
high levels are related to an increased risk of adverse events.2
Recently it has been demonstrated that BNP and N-termi-
nal pro-B-type natriuretic peptide (NT pro-BNP) also provide
predictive information on acute coronary syndromes (ACSs),
and they appear related to the severity of CAD in patients
affected with ACS.3,4
Acute coronary syndromes without ST elevation encom-
pass a wide range of events and have different prognostic
values in relation to the type of plaque lesions and the diffu-
sion of coronary atherosclerosis. The risk assessment, based
on clinical history and examination, electrocardiographic
(ECG) characteristics, andmarkers of myocardial damage, still
remains relatively inaccurate.5
The risks of subsequent death and/or recurrent ischemic
events also vary widely, depending on the presence of
myocardial ischemic areas, irreversible myocyte injury, the
hemodynamic consequences of ischemia and the extent of
coronary atherosclerosis.
Several studies in ACS patients demonstrated a strong as-
sociation between increased BNP levels and poor clinical
outcome; however, the underlying mechanisms responsible
for this association are not well clarified: BNP and pro-BNP
could be indicators for multivessel disease, poor TIMI flow,
as well as markers of coronary disease extension.4,6,7
To support this hypothesis, a few studies has been done
but they are limited by their retrospective nature, being a
subgroup of a trial, not having information about LV functions
or small sample size.8
So we planned this study to better assess the role of BNP in
assessing severity of CAD in real world practice in a pro-
spective manner with well defined patient inclusion and
exclusion criteria among a spectrum of Non ST Elevation ACS
Patients.
We compared BNP levels in patients with Unstable angina
and Non ST Elevation MI in relation to angiographic lesions,
vessel narrowing, and the extension of coronary disease,
using Gensini Score.2. Material and methods
2.1. Study population
The study was performed on the 197 consecutive subjects
(males-154, females-43) who presented to our department
with ACS with no ST elevation, and underwent coronary
artery angiography in our Department from May 2012 to Feb
2013.
UA was defined by ECG ST segment depression or promi-
nent T-wave inversion with negative Troponins with any of
the following: Rest angina e lasting for 20 min or more
 New onset angina e of at least CCS class 3 severity started
in preceding one month
 Increasing Angina e previously diagnosed angina that has
become distinctly more frequent, longer in duration or
lower in threshold (i.e. increased by 1 or more CCS class to
at least class 3 severity).9
NSTEMI was diagnosed when an elevation of troponin-I
levels (more than 1.0 ng/ml in any sample during the first
12 h post-admission) occurred, with or without ST/T changes
in the ECG, in the presence of features of UA.9
Patients were evaluated prior to blood sampling to deter-
mine their heart failure status according to the New York
Heart Association. All recruited patients underwent echocar-
diographic examination (Philips IE33) to evaluate wall motion
abnormality, left ventricular morphology and systolic func-
tions.10 Blood samples for BNP were performed within 12 h of
hospital admission and written informed consent was ob-
tained from all patients. coronary angiographywas performed
within first 3 days of hospital admission. Study was approved
by local research ethical committee.
2.1.1. Exclusion criteria
Patients with a history of myocardial infarction, ST elevation
on admission ECG, Evolution of ECG showing New LBBB or
New Q waves, valvular disease, acute or chronic heart failure,
cardiomyopathy, systolic dysfunction with ejection fraction
<50%, renal, liver, neoplastic, inflammatory and infectious
diseases were excluded.
2.2. Treatment protocol
All patients underwent standard therapy as per discretion of
treating cardiologist.
2.3. Laboratory assays
Plasma BNP and Troponin-I were immediately analyzed on
the same EDTA-anti-coagulated blood sample collected on
admission using the quantitative immunofluorescence assay
manufactured by Biosite (San Diego, CA, USA). The analytic
sensitivity of the BNP assay is <5 pg/Ml and for Troponin-I is
<0.1 ng/ml.
2.4. Angiographic analysis
All coronary angiograms were evaluated at the angiographic
core laboratory by physicians who were blinded to the
patient’s clinical or BNP status.
Coronary stenosis was quantified using validated quanti-
tative coronary angiography by the consensus opinion of two
experienced interventional cardiologists with >50% diameter
stenosis considered as significant. Assessment of epicardial
coronary flowwas done using the TIMI flow grade according to
established methods.11 The Gensini Score (GS) was used to
assess the burden of coronary arteriosclerosis.12 The GS
system yields a qualitative and quantitative evaluation of the
coronary angiogram; it grades the narrowing of the lumen of
the coronary artery as 1 for 25% narrowing, 2 for 26e50%
Table 2 e Clinical characteristics and associated risk
factors in patients with BNP<80 and>80 pg/ml.
BNP <80
(N ¼ 104)
BNP >80
(N ¼ 93)
P value
Age (mean  SD) 52.7  10.4 54.3  11.5 0.332
Diabetes (%) 11 (10.6) 14 (15.1) 0.345
Hypertension (%) 31 (29.8) 45 (48.4) 0.008
Smoking (%) 63 (60.6) 62 (66.7) 0.375
Dyslipidemia (%) 41 (44.1) 44.09 0.575
USAP (%) 85 (81.7) 54 (58.1) 0.012
NSTEMI (%) 19 (18.3) 39 (41.9) 0.0003
Triple vessel disease (no.) 03 32 <0.001
Gensini Score (mean  SD) 13.4  16.5 40.9  29.7 <0.001
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16 for 91e99% narrowing, and 32 for total occlusion. This
primary score is multiplied by a factor that takes into account
the importance of the position of the lesion in the coronary
arterial tree (5 for the left main coronary artery, 2.5 for the
proximal left anterior descending artery or proximal left
circumflex artery and 1.5 for the mid-region, 1 for the distal
left anterior descending artery, and 1 for the mid-distal region
of the left circumflex artery or right coronary artery). In our
study, the GS was expressed as the sum of the scores for all
three coronary arteries in order to evaluate the entire extent of
CAD.
2.5. Statistical analysis
The statistical analysis was performed using the SPSS soft-
ware for Windows, version 13.0 (SPSS, Inc., Chicago). Sum-
mary statistics for continuous variables were recorded as the
mean  SD and the categorical data was summarized as
frequencies and percentages. Correlations between contin-
uous variables were calculated according to Spearman-Rho.
logistic regression analysis was performed with the extent of
CAD, smoking, diabetes, hypertension and dyslipidemia as
the dependent variable and BNP level as independent variable.
odds ratio (OR) is presented with 95% confidence intervals. All
numeric data are presented as themean SD, and a p value of
less than 0.05 was considered statistically significant.3. Results
3.1. BNP and clinical presentation
Clinical characteristics and associated risk factor are reported
in (Table 1). BNP levels were significantly higher in the NSTEMI
Group in comparison to the USAP Group and (161  149.3 vs
79.6  94.2 pg/mL; p < 0.001).
BNP >80 pg/mL was recruited in 39 of 58 (68%) patients of
NSTEMI while 54 of 139 (39%) of USAP patients were recruited.
Triple vessel disease was revealedmore frequently in patients
with BNP >80 pg/mL e 32 out of 35 (91%) patients of Triple
vessel disease had BNP >80 pg/ml. Except for hypertension
which was more common in patients with BNP >80 pg/ml,
other risk factors were equal in both groups (Table 2).
3.1.1. BNP and coronary vessel involvement
BNP was strictly related to the extent of coronary disease:
significant progressive differences were assessed between theTable 1 e Clinical characteristics and risk factors.
USAP
(n ¼ 139)
NSTEMI
(n ¼ 58)
p value
NO. 139 58 e
Male 106 (76.3) 48 (82.8) 0.314
Diabetes (n) 15 (10.8) 10 (17.2) 0.215
Hypertension (n) 47 (33.8) 29 (50.0) 0.033
Smoking (n) 85 (61.2) 40 (69.0) 0.299
Dyslipidemia (n) 70 (50.4) 21 (36.2) 0.069
BNP (pg/ml) mean  SD 79.7  94.2 161.4  149.3 <0.0011-vessel group, the 2-vessel and 3-vessel group (1-vessel
51.4  31.6; 2-vessel 114.0  67.8; 3 vessel 265.4  188.8 pg/
mL, p < 0.001). A similar significant trend was found between
the 1-vessel group and the 2-vessel. group (p < 0.01), 2-vessel
group and 3-vessel group (p < 0.01). When the measurement
was limited to the 1-vessel group (n ¼ 117), we observed a
significantly higher BNP in patients with left anterior
descending artery (LAD) involvement than in patients with
other coronary artery involvement (64.78 vs 49.76 pg/mL,
p < 0.05) (Table 3).
The analysis of the Gensini Score (GS) demonstrated a
strong correlation between coronary artery disease extension
and BNP levels (r ¼ 0.675, p < 0.01) (Fig. 1). Gensini Score was
significantly higher in those with BNP> 80 vs < 80 pg/ml
(40.9  29.7 vs 13.4  16.5 p < 0.001).
BNP> 80 pg/ml was found to strongly predict the presence
of TVD (odds ratio 18.87; 95% confidence intervals 5.36e66.36),
and DVD (odds ratio 3.62; 95% confidence interval 1.75e7.47)
but also associated with hypertension (odds ratio 2.67; 95%
confidence intervals 1.28e5.59) (Table 4).4. Discussion
Many studies have shown that the elevation of BNP levels, as
well as NT-proBNP levels, obtained after the acute phase in
patients with a broad range of ACS independently predicts
mortality. However, in most of the reports, authors did not
distinguish between subjects with low ejection fraction and
LV enlargement.3,4,13 Because of its release in response to
increased ventricular chamber pressure or wall tension, in
ACS patients with decreased LV ejection fraction, elevated
BNP levels reflect a high degree of myocardial dysfunction,
with a higher risk of death and congestive heart failure.
The main finding of our study is that BNP levels are related
also to the severity of coronary atherosclerosis: patients with
multi-vessel disease showed higher BNP levels than subjects
with only one or two vessel involvement. This trend wasTable 3 e BNP and extent of CAD.
SVD DVD TVD p value
No 117 45 35
BNP (pg/ml) 51.9  31.9 114.0  67.8 265.4  188.8 <0.001
Gensini Score 13.4  9.9 35.6  26.3 58.80  35.5 0.007
140.00120.00100.0080.0060.0040.0020.000.00
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Fig. 1 e Correlation of BNP and Gensini Score.
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Elevation of BNP levels appears strictly related to coronary
artery disease.
Our results are in accordance with those of Sadanandan
et al showing a correlation between TIMI flow, tightness of
culprit stenosis and BNP levels.8 However, with respect to the
cited study, our sample was characterized by the absence of
left ventricular dysfunction and enlargement, which are the
main factors responsible for BNP increase.14,15 Again, we
demonstrated that BNP threshold of 80 pg/ml appears able to
predict the extension of coronary disease independently from
LV systolic dysfunction and enlargement. The same value has
been previously recognized as cutoff for mortality and risk for
adverse events in patients with ACS.3,4,8 Our results are also in
accordance with study by Alberto Palazzuoli et al16 but the
cited study was retrospective in nature.
Most importantly our study strongly showed that high BNP
(>80 pg/ml) is a strong predictor of Triple vessel disease irre-
spective of diagnosis of USAP or NSTEMI. The exact mecha-
nisms of natriuretic peptides rise in coronary disease are not
completely understood. Ischemia may constitute an inde-
pendent stimulus for BNP release towards a transientTable 4 e Age and sex adjusted prevalence of traditional
risk factors & CADmagnitude (odd ratio, 95% confidential
intervals, logistic regression) in high BNP patients (>80)
compare to low BNP level (BNP £80).
Variables BNP>80
(n ¼ 93)
BNP 80
(n ¼ 104)
p value
Diabetes 1.65 (0.69e3.94) 1 0.257
Hypertension 2.67 (1.28e5.59) 1 0.009
Smoking 1.25 (0.64e2.46) 1 0.509
Dyslipidemia 0.86 (0.49e1.52) 1 0.616
SVD 0.95 (0.05e0.19) 1 <0.001
DVD 3.62 (1.75e7.47) 1 <0.001
TVD 18.87 (5.36e66.36) 1 <0.001decrease of systolic function and compliance, reflecting not
only the impairment in left ventricular function, but also the
severity of the ischemic insult.17 Alternatively, BNP secretion
may be due to the augmented regional wall stretch which
occurs during ischemic attacks even in the absence of pump
dysfunction inducing the neurohormonal activation.18 The
detection of BNP gene expression in ischemic and infracted
regions together with BNP receptor recruitment in coronary
plaques could explain a novel mechanism of BNP
induction.19,20
The strong correlation between the Gensini Score and BNP
levels extend previous findings demonstrating that a further
stimulus for BNP increase could be the severity and diffusion
of coronary plaques that, consistent with this observation,
lead to a worsening of the ischemic myocardial area.18,21
All together these data could explain the mechanisms
linking BNP to an adverse outcome in CAD, it represents a
marker of coronary disease severity and is related to the
presence of plaques diffusion and narrowing. For the above
mentioned reasons BNP should be considered as an indicator
of regional ischemia and as a predictor for adverse events in
patients with chest pain.22,235. Study limitations
The present study suffers from few limitations, the major one
is the small sample size. However our sample was carefully
defined and selected on the basis of echocardiographic and
clinical criteria. Age and sex could have influenced the find-
ings even if the population studied had almost similar
demographic characteristics in all groups. We did not
compare BNP levels to other biomarkers of myocardial injury
such as Troponin, high sensitive CRP or cytokine levels.6. Conclusions
BNP represents a biomarker for left ventricular dysfunction
and enlargement as well as for myocardial ischemia. It
appears it is able to give additional prognostic information to
existing traditional biomarkers (i.e. troponin and C-reactive
protein). BNP is a candidate for entry into the setting of prin-
cipal risk scores. Our findings indicate that the level of BNP
may reflect the extent or severity of ischemic insult even
when irreversible injury and systolic dysfunction have not
occurred and strongly predict the presence of Triple vessel
disease.Conflicts of interest
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